[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgery":635},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,284,0,25,[9,42,68,89,113,134,157,185,209,233,262,285,310,333,356,390,415,435,457,486,514,536,560,585,611],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053385",false,"NCT06289686","Rotator Cuff Repairs With or Without BioEnthesis™ Augmentation","Inclusion Criteria:\n\n* DEERS-eligible\n* Adults, between the ages of 18-65 (inclusive)\n* Presenting with a rotator cuff tear that is reparable surgically (a reparable tear is defined as tear of the RC where it is possible to bring the retracted tendon edge back to the greater tuberosity of the humerus under minimal tension)\n* Ability to undergo surgery to repair rotator cuff tear\n* Willingness to commit to study procedures including study intervention and a 12-month follow-up\n* Fluency in speaking, reading, comprehending English\n* 1-2 tendon full thickness reparable RC tear (full thickness tear is defined as a tear that involves the majority of supraspinatus and less than half of the infraspinatus under minimal tension, with no subscapularis involvement beyond the upper border)\n* Patients who have high-grade partial thickness tears where the surgeon elects to complete the tear during surgery before repairing the tendon(s)\n\nExclusion Criteria:\n\n* Previous shoulder surgery (excluding acromioplasty or diagnostic arthroscopy)\n* Inability to receive an MRI\n* Current (within the past 6 months) tobacco user\n* Unwilling to remain tobacco free for the duration of the study\n* Current lower limb injuries requiring walking assist devices such as crutches and walkers\n* Diagnosed with systemic arthritis\n* Significant neck pathology\n* Active joint or systemic infection\n* Currently enrolled, or plans to enroll, in another clinical trial during this study (that would affect the patient's safety or results of this trial)\n* Significant muscle paralysis of the shoulder girdle\n* Currently pregnant or plans to become pregnant during this study\n* Inability of the surgeon to repair the tear with remaining defect no greater than 10 mm in diameter\n* Inability of the surgeon to repair the tear with less than 1cm of medialization\n* Evidence of other significant shoulder pathology (such as Grade III osteoarthritis)\n* Has a history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction\n* Major medical illness that would preclude undergoing surgery\n* Major psychiatric illness or developmental handicap\n* Goutallier III classification and above","ALL","18 Years","65 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Rotator cuff (RC) injuries are particularly prevalent, difficult to repair, and attachment between the bone and tendon is notoriously difficult to achieve. The most common method and current standard of care (SOC) for reattaching connective tissues (e.g., ligaments, tendons) to bone typically involves suture anchor-based techniques, but this is fraught with problems. More specifically, re-tearing of the connective tissue after this procedure occurs in 30-60% of cases, and can be even higher in patients who engage in smoking, have a diagnosis of diabetes, etc. To address these clinical challenges, Sparta Biopharma Inc. (Sparta) developed a unique technology, called BioEnthesis, to improve the connection between the tendon and bone. Pre-clinical in vivo studies demonstrated that the biphasic bovine cancellous matrix regenerated at the bone-soft tissue interface-thereby leading to high structural integrity and will likely lead to reduced re-tear rates over time. The investigators hypothesize that patients in this interventional cohort will experience enhanced mobility, reduced pain, and less re-tears after RC procedures versus a standard suture anchor-based repair.",[26,27,28],"Rotator Cuff Tears","Rotator Cuff Injuries","Surgery","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2023-07-28",{"date":37,"type":20},"2027-08",{"name":39,"class":40},"Brooke Army Medical Center","FED",5,{"id":43,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100598834","NCT07076641","Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Morphine-rachi Analgesia","Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Analgesic Morphine Rachi Anesthesia for Major Digestive or Abdominal Surgery by Laparotomy.","LIDORACHI","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Major digestive or abdominal surgery (pancreatic, hepatic, colorectal, gynecological, esophageal, gastric, duodenal, small intestine...);\n* Scheduled surgery;\n* Laparotomy;\n* Patient in agreement with morphine rachi anesthesia;\n* Social security affiliation;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Contraindication to non-steroidal anti-inflammatory drugs: history of gastro duodenal ulcer, renal failure from stage 3 A or higher;\n* History of bradycardia and\u002For known conduction disorder (atrioventricular block) \u002F Pacemaker ;\n* Unstable coronary ;\n* Myocardial infarction \\\u003C6 months;\n* Severe cardiocirculatory insufficiency;\n* Severe hepatic insufficiency;\n* Allergy to morphine ;\n* Allergy to lidocaine;\n* Rhythm disorders at risk of sudden death (e.g. Brugada syndrome);\n* Flecaine as usual treatment;\n* Chronic pain with level II or III analgesics;\n* Gabapentinoids: pregabalin (Lyrica), gabapentin;\n* Drug addiction and substitute drugs;\n* Epileptic disorders ;\n* Myasthenia gravis;\n* Creatinine clearance below 10 mL\u002Fmin;\n* Hypokalemia, hypoxia or acid-base disorders;\n* Patient participating in another clinical trial, or in a period of exclusion from another clinical trial;\n* Inability to understand study information (due to linguistic, psychological, cognitive or literacy problems);\n* Women who are or may become pregnant\\* (of childbearing age, without effective contraception) or who are breast-feeding;\n* Patient deprived of liberty, under guardianship or unable to give consent.",{"count":50,"type":20},76,[52],"PHASE3","The purpose of this study is to evaluate the superiority of IV lidocaine combined with morphine spinal anesthesia versus placebo combined with morphine spinal anesthesia, in reducing postoperative morphine consumption at 48 hours, in patients undergoing major digestive or abdominal surgery by laparotomy.",[55,28],"Digestive System Disease","NOT_YET_RECRUITING","2026-06-30",{"date":59,"type":33},"2026-07-01",{"date":61,"type":20},"2026-07",{"date":63,"type":20},"2027-07-30",{"name":65,"class":66},"GCS Ramsay Santé pour l'Enseignement et la Recherche","OTHER",1,{"id":69,"slug":4,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":67},"100633588","NCT07528638","Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND)","Feasibility of Using Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) to Provide Early Identification and Protection of the Intercostalbrachial Nerve (ICBN), Medial Branch Cutaneous Nerve (MBCN), and Their Branches","Inclusion Criteria:\n\n1. Patients ages 18-70 years old.\n2. Pathologically confirmed diagnosis of breast cancer.\n3. Undergoing ALND by one of the breast surgeon Sub-Investigators on this study.\n\nExclusion Criteria:\n\n1. Patients having any previous axillary surgery other than percutaneous breast biopsy and\u002For SLNB.\n2. Prior breast radiation with neuropathy clearly developing after radiation.\n3. Patients who have undergone prior chemotherapy and developed post-chemotherapy neuropathy prior to ALND.\n4. Patients with any pre-existing neurological conditions affecting nerves, such as neuropathy (peripheral neuropathy, neuropathic pain or nerve injury to upper extremity).\n5. Patients taking medications that are known to modify neuropathic pain (eg, gabapentin, pregabalin, duloxetine, venlafaxine, lidocaine patches, capsaicin, opioids, tramadol, NMDA receptor antagonists, clonidine, cannabis, botox).\n6. Patients with prior spinal surgery or spinal pathology (cervical spinal stenosis or cervical radiculopathy).\n7. Patients with limb-dysfunction.\n8. Patients with demyelinating disease.\n9. Patients with significant co-morbidities (clotting disorders on anticoagulation, cardiac issues, other conditions that could impact long-term follow-up).\n10. Patients that present with pre-operative breast, arm or chest pain ipsilateral to anticipated ALND.\n11. Patients who have had prior procedures where IONM failed intraoperatively.\n12. Presence of parietal cortical lesion.","70 Years",{"count":76,"type":20},6,[78],"NA","The purpose of this study is to determine whether the implementation of existing neurosurgical techniques of intraoperative neuromonitoring (IONM) and the replacement of monopolar electrocautery with bipolar electrocautery (BE), during ALND, will improve the early identification of nerves that have been implicated in the cause of neuropathically-mediated post-surgical pain syndrome (PSPS).",[81,28],"Breast Cancer","2026-06-29",{"date":59,"type":33},{"date":82,"type":33},{"date":86,"type":20},"2027-12-01",{"name":88,"class":66},"University of Cincinnati",{"id":90,"slug":4,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":67},"100543491","NCT06356558","Adapting Enhanced Recovery Programs for Low Health Literacy Patients","Inclusion Criteria:\n\n* Adult patients \\>= 18 years of age undergoing surgery under an enhanced recovery program (ERPs)\n* Adult caregivers\u002Fproviders, organizational leaders, \\>= 18 years of age with direct or indirect involvement with ERP implementation\n* All genders\n* All race\u002Fethnicities\n* Able to consent\n* English-speaking\n\nExclusion Criteria:\n\n* Child (\\\u003C18 years of age)\n* Patients undergoing operations not included under ERPs\n* Participants unable to consent for the study\n* Participants whose mental state excludes them from being able to understand contents of the informed consent form and\u002For patients whose family members or patient representative do not wish for them to participate in the study",true,{"count":96,"type":20},1050,[78],"Low health literacy patients are a vulnerable population at high-risk for surgical disparities including longer hospital stays, more complications, and more readmissions. This study will adapt enhanced recovery programs (ERPs) to low health literacy patients with a multilevel, health literacy-based implementation strategy (called VISACT - VISuAl aids, Coach providers in communication, and Train organizations in health literacy) to improve ERP fidelity and thereby outcomes. In the final aim of this project (Specific Aim 3), the VISACT intervention will be tested in a pilot trial. Findings from this study will lay the foundation for a multi-institutional stepped-wedge trial and establish key principles for adapting interventions to eliminate disparities.",[28,100,101],"Health Knowledge, Attitudes, Practice","Colorectal Disorders",[28,103,104],"Health Literacy","Enhanced Recovery","2026-06-25",{"date":82,"type":33},{"date":108,"type":33},"2026-06-15",{"date":110,"type":20},"2028-05-01",{"name":112,"class":66},"University of Alabama at Birmingham",{"id":114,"slug":4,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":119,"minAge":16,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":67},"100392456","NCT04390230","Inflatable Penile Prostheses : Which Patients Can Correctly Use the Scrotal Pump ?","Inflatable Penile Prostheses : Predicting Factors of Pump Misuse and Unsatisfaction","All cases included were discussed and approved by a multidisciplinary team. Patients who underwent prosthesis replacement or second implantation were not included. We excluded patients who refused or were not able to answer our questionnaire, patients who provided unreliable answers, and patients that experimented a secondary malfunction of their IP.","MALE",{"count":121,"type":20},120,"OBSERVATIONAL","Sexual health and satisfaction are well know as critical critera to assess quality of life, at any age. Among the multiple aspects of sexual health, erectile dysfunction (ED) is not anymore a fate, mainly thanks to the advent of phosphodiesterase type 5 (PDE5) inhibitors in 1998. Nevertheless, a significant part of patients are intolerant or does not respond to PDE5 inhibitors and thus are looking for other treatment options.\n\nSince the first implantation of foreign material intracarvernosally in 1966 by Beheri, multiple modifications and enhancements were achieved in order to produce devices more reliable with a more natural appearance. First introduced in 1973 by Scott et al., inflatable prosthesis provides now high general satisfaction rates (69-94%), better than in malleable prostheses, except for few authors.\n\nIn addition to changes in materials and construction, the two main manufacturers of IPP, Boston scientific AMS (Marlborough, MA, USA) and Coloplast (Minneapolis, MN, USA), modernized the pump mechanism of their devices. Since the introduction of AMS IPP, three main pump formats have been used : the standard pump has been replaced in 2004 by the \" Tactile \" pump and then the \" Momentary Squeeze \" (MS) pump in 2006, smaller and easier to deflate by not requiring the patient to hold the deflation button throughout deflation. Coloplast also replaced in 2008 their \" Genesis \" pump by a \" One Touch Release \" (OTR) pump, and finally in 2014 by the current \" Touch \" pump, smaller, and presenting a biconcave deflation button, easier to find.\n\nDespite all technological advances, appropriate pre-operative counselling and careful post-operative teachning, a significant part of patients has still difficulties to handle the pump and thus, does not use their IPP, regardless of any material malfunction. That situation obviously leads to patient's dissatisfaction and highlights the operating risks of a useless surgical procedure.\n\nThe purposes of this study were:to identify the risks factors, modifiable and non-modifiable, for patients' difficulty to inflate and\u002For deflate their device after IPP implantation, then to show a correlation between easy handling and post-operative satisfaction. And last but not least, to show an association between pre-operative pump pattern viewing and handling and post-operative easy handling. That information could help the physicians to improve the pre-operative selection of patients and to adapt the peri-operative care in order to improve patients satisfaction.",[28,125,126],"Satisfaction","Penile Prosthesis; Complications",{"date":82,"type":33},{"date":129,"type":33},"2014-01-24",{"date":131,"type":20},"2027-06-25",{"name":133,"class":66},"Centre Hospitalier Universitaire de Nice",{"id":135,"slug":4,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100644297","NCT07664514","FOCUS Pre-Post Study","Facilitating Goal-based Conversations for Understanding Surgery (FOCUS) Guide: Pre-Post Study","Inclusion Criteria:\n\nFor surgeons\n\n1\\. Surgeons who have regular outpatient clinics at the University of Utah and Huntsman Cancer Institute\n\nFor patients:\n\n1. Age ≥65 years.\n2. Presenting for in-person outpatient consultation regarding major non-urgent surgery with an enrolled surgeon.\n3. Ability to provide informed consent.\n4. English-speaking.\n\nExclusion Criteria:\n\nFor surgeons\n\n1. Surgeons with a predominantly pediatric practice\n2. Transplant surgeons\n\nFor patients\n\n1. Anticipated life expectancy \\\u003C3 months.\n2. Inability to complete study procedures.\n3. Patients presenting for minor procedures or non-operative consultations.\n4. Telehealth consultation\n5. Any clinical, cognitive, communication, or logistical factor that, in the opinion of the treating surgeon or investigator, would substantially interfere with participation or completion of study procedures.",{"count":141,"type":20},180,[78],"The Facilitating Goal-based Conversations for Understanding Surgery (FOCUS) Guide is a communication intervention designed to support discussion and documentation of the goal for surgery during outpatient surgical consultations. The purpose of this study is to assess the efficacy of the FOCUS guide in prompting discussion of the goal for surgery.",[28],[28,146,147],"Goals","Communication guide","2026-06-23",{"date":150,"type":33},"2026-06-26",{"date":152,"type":20},"2026-08-15",{"date":154,"type":20},"2029-05",{"name":156,"class":66},"University of Utah",{"id":158,"slug":4,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":94,"sex":163,"minAge":164,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100540075","NCT06312124","A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer","A Multi-Disciplinary Approach to the Opportunistic Salpingectomy for Primary Prevention of Ovarian Cancer","Inclusion Criteria:\n\nPart I\n\n* Age ≥45 years\n* Scheduled visit with a nongynecologic surgeon\n* Female or assigned female at birth\n\nPart II\n\n* Age ≥45 years\n* At least one in situ fallopian tube\n* No desire or plan to have children in the future\n* Average risk of developing ovarian cancer\n\n  ° Note: Average risk patients are defined as patients with no known genetic risk factor for developing ovarian cancer. Patients who, after obtaining family history, are suspected to have a hereditary ovarian cancer syndrome but have not yet been tested, will be referred for genetic evaluation.\n* Planned nongynecologic, intraabdominal, or pelvic surgery\n* Deemed to be a suitable candidate by gynecologic surgeon and primary nongynecologic surgeon (for example, on the basis of surgical history and current malignancy status)\n* Approved and signed informed consent\n\nExclusion Criteria:\n\nPart I\n\n* Not fluent in English or Spanish\n\n  ° If there is a non-english or non-spanish speaking participant who is a strong candidate and meets all other criteria for Part 2, they are able to go directly onto Part 2 without completing Part 1. (Please see additional details in section 4.1 and 7.0.)\n* Known inherited ovarian cancer susceptibility\n\nPart II\n\n* Personal history of a gynecologic malignancy\n* Carrier of a hereditary breast or ovarian cancer variant (e.g., BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2)\n* Suspicious ovarian, fallopian tube, or uterine lesion on preoperative imaging\n* Previous bilateral salpingectomy or bilateral salpingo-oophorectomy\n* Presence of ESSURE, or other tubal-implanted birth control at the time of surgery\n* Current pregnancy\n* Emergent procedure or emergency procedure that has to be completed within 24 hours where clinical consent occurs in the inpatient setting or where the patient's immediate well-being is in danger or condition may be life threatening\n* Primary surgeon anticipates that OS will add significant time (\\>30-40min) to the planned procedure.\n* Inability to access the pelvis (ex., patient prone\u002Flateral position) during the planned procedure.\n* Known history of pelvic fibrosis or significant adhesions.\n* Procedures with palliative intent only","FEMALE","45 Years",{"count":166,"type":20},266,[78],"The purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. Before and after watching the video, participants will complete questionnaires in the clinic.",[28],[171,172,173,174,175,176],"abdominal surgery","pelvic surgery","Opportunistic Salpingectomy","ovarian cancer prevention","24-006","Memorial Sloan Kettering Cancer Center",{"date":178,"type":33},"2026-06-24",{"date":180,"type":33},"2024-03-08",{"date":182,"type":20},"2028-03-08",{"name":176,"class":66},10,{"id":186,"slug":4,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":122,"phases":4,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":67},"100577856","NCT06803732","Postoperative Pain of Robotic, Endoscopic and Open Lateral Neck Dissection","Inclusion Criteria:\n\n* Patients underwent lateral neck dissection via robotic, endoscopic or open approach\n* Clinical diagnosis of differentiated thyroid cancer\n* Clinical diagnosis of metastatic lateral lymph nodes\n\nExclusion Criteria:\n\n* Participants with distant metastasis\n* Participants with history of neck surgery or radiation\n* Participants with vocal fold fixation by preoperative fibrolaryngoscope",{"count":191,"type":20},600,"6 Months","Postoperative pain is a good indicator to confirm the advantages of the surgical methods in the era of minimally invasive surgery. Lateral neck dissection requires extensive dissection which may leads to postoperative numbness and pain. Robotic thyroid surgery has the advantage of precise and careful dissection and avoid the L-shape incision in the open approach. The study aims to explore the pain intensity and severity of lateral neck dissection on operation day, postoperative month 1 and postoperative month 3 among the robotic, endoscopic and open approach.",[195,196,28],"Pain, Postoperative","Thyroid Diseases",[198,199,200],"Lateral neck dissection","Robotic thyroid surgery","Minimally invasive surgery","2026-06-20",{"date":178,"type":33},{"date":204,"type":33},"2024-11-01",{"date":206,"type":20},"2027-12-31",{"name":208,"class":66},"Shanghai 6th People's Hospital",{"id":210,"slug":4,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100641397","NCT07659730","Evaluation of a Structured Hospital-Community Care Follow-up Based on Perceived Quality of Care After Surgery, Aimed at Reducing Persistent Opioid Use in Primary Care: a Pragmatic Randomized Controlled Trial","OPIOID CITY FR","Inclusion Criteria:\n\n* Male or female\n* Adult patient, with no upper age limit\n* Undergoing scheduled or unscheduled surgery in a center participating in the research\n* Subject affiliated to a social health insurance scheme\n* Subject able to understand the objectives and risks related to the research and to give informed consent, dated and signed\n\nExclusion Criteria:\n\n* Inability to administer the mQoR-15f questionnaire (cognitive disorders, language barrier)\n* Patient who has already received previous follow-up by the OPTIMISTE team\n* Patient enrolled in a therapeutic trial that may affect post-operative recovery quality.\n* Pregnant or breastfeeding woman\n* Inability to provide the subject with informed information (subject in an emergency situation, difficulties in understanding, etc.)\n* Subject under legal protection, guardianship or curatorship",{"count":216,"type":20},772,[78],"The OPTIMISTE program is based on a structured postoperative follow-up centered on patients' subjective perception of recovery using validated Patient Reported Outcome Measures (PROMs), including the mQoR-15f score. Follow-up is delivered by specifically trained nurses and embedded in a decompartmentalized care model combining in-person and remote interactions, integrating hospital teams and primary care professionals within a coordinated pathway.\n\nOPTIMISTE was recently evaluated in a multicenter randomized controlled trial, the SUPPORT study (NCT06182254), which included 280 patients. The study demonstrated a significant impact of PROM-based follow-up on perceived recovery at postoperative day 35, and more importantly, an approximately 50% reduction in the proportion of patients with persistent opioid use at that time point. Although this was a secondary endpoint, the findings suggest that active postoperative monitoring centered on patient-reported outcomes and rapidly relayed to community care providers represents a major lever for preventing opioid misuse after surgery.\n\nHowever, these results require further confirmation and refinement. First, the effect on persistent opioid consumption needs to be validated as a primary endpoint. Second, despite the benefit observed, more than 12% of patients in the intervention group still exhibited persistent opioid use five weeks after surgery, compared with 21% in the control group. This residual persistence, although reduced, remains clinically concerning and indicates that the current OPTIMISTE model does not yet fully prevent unanticipated prolonged opioid exposure.\n\nThe hypothesis of the present protocol is that the effectiveness of OPTIMISTE in reducing postoperative persistent opioid use can be strengthened through earlier, more individualized and primary-care-driven management. This enhancement relies on better mobilization of community healthcare professionals - general practitioners, community nurses and pharmacists - supported by digital health tools and reinforced coordination channels such as secure platforms, teleconsultations and structured transmission of PROM scores.\n\nBy systematically integrating primary care providers into longitudinal postoperative follow-up guided by PROMs, the protocol aims to improve therapeutic responsiveness, reduce unjustified prolonged prescriptions and promote early tapering when clinically appropriate. The objective is to optimize hospital-community coordination in order to amplify the impact of the OPTIMISTE pathway on patient-perceived recovery and opioid stewardship.\n\nUltimately, this research seeks to demonstrate that strengthening the role of primary care, combined with fine-grained assessment of patient-reported recovery, represents an effective, ethical and scalable strategy to improve the quality, safety and efficiency of postoperative care pathways while sustainably reducing persistent opioid use at both individual and population levels.",[220,28],"Perioperatoire Medicine",[222,28,223,224],"Perioperative","Patient Reported Outcomes Mesuares (PROMs)","persistent opioid use",{"date":226,"type":33},"2026-06-22",{"date":228,"type":20},"2026-07-02",{"date":230,"type":20},"2029-12-01",{"name":232,"class":66},"University Hospital, Strasbourg, France",{"id":234,"slug":4,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":15,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":21,"phases":243,"briefSummary":244,"conditions":245,"keywords":251,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":67},"100641453","NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study","Inclusion Criteria:\n\n* Age 50 to 80\n* Able to speak and understand English\n* Scheduled to undergo a surgery meeting the following criteria: (1) traditional open surgery (not laparoscopic or robotic) via laparotomy (midline or subcostal incisions), (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces\n* Participant reports pain intensity of 4\u002F10 or above to study staff on day 1 post-surgery or any other day post-surgery through discharge\n\nExclusion Criteria:\n\n* Significant visual impairment that has not been corrected\n* Significant hearing impairment that has not been corrected\n* Significant cognitive impairment that would prevent participant from participating in the study","50 Years","80 Years",{"count":242,"type":20},20,[78],"Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.",[28,246,247,248,249,250],"Stomach Cancer","Pancreas Cancer","Bile Duct Cancer","Liver Cancer","Peritoneal Cancer",[252,253],"Music therapy","Music-assisted relaxation and imagery",{"date":255,"type":33},"2026-06-17",{"date":257,"type":20},"2027-01",{"date":259,"type":20},"2027-12",{"name":261,"class":66},"Case Comprehensive Cancer Center",{"id":263,"slug":4,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":15,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":284},"100632484","NCT07514286","Assessment of the Feasibility and Organisational Impact of a Care Pathway Incorporating the MultiSense® Medical Device for Post-operative Home Monitoring of Elderly Patients.","IMPACT - MS","Inclusion Criteria :\n\n* Patient aged 65 or over\n* Patient eligible for remote monitoring using the MultiSense® device\n* No psychiatric illness that would prevent them from giving informed consent or receiving optimal treatment and follow-up care\n* Subject affiliated with a health insurance scheme\n* Subject able to read and understand English\n* Subject who has signed an informed consent form\n* Subjects indicated for scheduled surgery\n* Patients indicated for scheduled surgery :\n\n  * Transverse colectomy, by laparotomy\n  * Hepatic laparoscopy\n  * Laparoscopic or laparoscopic liver surgery (code hlfc or hlfa for procedures)\n  * Hysterectomy\n  * Adnexectomy\n  * Parietal surgery (eventration)\n  * Rectal resection\n  * Right and left colectomy\n  * Stoma closure by direct approach\n\nExclusion Criteria :\n\n* Patients already participating in an interventional clinical trial.\n* Patients subject to legal protection measures, guardianship, curatorship, or deprived of their liberty by judicial or administrative decision.\n* Patients hospitalised without consent.\n* Patients unable to complete a questionnaire and without a close relative to assist them in using the solution.\n* Patients admitted to or residing in a health or social care facility (other than for the surgery itself).\n* Persons admitted to or residing in a health or social care institution (other than for the surgery itself);\n* Persons unable to give their free and informed consent.",{"count":269,"type":20},80,[78],"Assessing the clinical and organisational impact of a home-based post-operative monitoring strategy incorporating the MultiSense® device involving 80 patients aged 65 years and over who have undergone major surgery.",[273,28],"Average Length of Stay",[275],"Remote monitoring",{"date":255,"type":33},{"date":278,"type":33},"2026-06-03",{"date":280,"type":20},"2027-02-01",{"name":282,"class":283},"Rhythm Diagnostic Systems","INDUSTRY",4,{"id":286,"slug":4,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":21,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":308,"locationsCount":67},"100560314","NCT06575530","Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation","Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 and 64 years\n* Scheduled to undergo elective non-cardiac surgery\n* Planned for general anesthesia\n* With or without combined regional nerve blockade\n* Admitted to the ICU with endotracheal intubation post-surgery\n* With an anticipated duration of postoperative mechanical ventilation greater than 24 hours\n* Clinically requiring light sedation( target RASS score 0 to -2)\n\nExclusion Criteria:\n\n* Undergoing intracranial surgery, or having a history of severe neurological or spinal cord diseases\n* Pre-existing history of schizophrenia, epilepsy, or Parkinson's disease\n* Inability to communicate preoperatively due to coma, severe dementia, or language barriers\n* Preoperative .cardiac insufficiency or severe cardiac arrhythmias\n* Severe hepatic impariment( Child-Pugh class C)\n* Severe renal impariment\n* Preoperative( within 24 hours prior to surgery) or intraoperative administration of dexmedetomidine or remimazolam\n* Pregnancy or lactation\n* Participation in any clinical trial involving investigational drugs within 30 days prior to enrollment\n* Any other conditions deemed by the investigators to render the patient unsuitable for study participation\n* Refusal to provide written informed consent","64 Years",{"count":293,"type":20},306,[23],"A multi-center, prospective, randomized, double-blind, active-controlled, no-inferiority clinical trial conducted across 5 tertiary medical centers in China. The objective of this RCT is to evaluate the sedative efficacy and safety profile of remimazolam besylate compared with dexmedetomidine in patients requiring mechanical ventilation following non-cardiac surgery. The study hypothesized that remimazolam besylate is non-inferior to dexmedetomidine regarding the primary efficacy outcome.",[297,298,299,300,28,301],"Effect of Drug","Adverse Drug Event","Mechanical Ventilation Complication","Critical Illness","Sedation","2026-06-13",{"date":304,"type":33},"2026-06-16",{"date":306,"type":33},"2025-01-20",{"date":57,"type":20},{"name":309,"class":66},"Beijing Shijitan Hospital, Capital Medical University",{"id":311,"slug":4,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":316,"targetDuration":4,"studyType":21,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":67},"100620761","NCT07361822","Comparison of Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes of Intravenous PCA Following Mixed Surgery","Prospective Randomized Controlled Study of Individualized PCA Model Based on Multi-dimensional Strategies (Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes)","Inclusion Criteria:\n\n* aged between 18 to 65 years;\n* American Society of Anesthesiologists physical status Ⅰ - Ⅲ;\n* Patients scheduled for elective mixed surgery were enrolled. Mixed surgeries included thoracic, abdominal, spinal, orthopaedic, and cranial procedures performed using either minimally invasive or open approaches.\n\nExclusion Criteria:\n\n* Allergy to PCA medications;\n* Presence of chronic pain syndromes;\n* Presence of psychiatric disorders, or severe cardiovascular, cerebrovascular, renal, or hepatic dysfunction.",{"count":317,"type":20},1170,[78],"Perioperative pain management affects patient recovery. However, the rate of moderate to severe postoperative pain is as high as 73.8%, which hinders recovery and increases the risk of complications. Although opioids are the first-line analgesics, excessive use leads to adverse reactions. The traditional fixed-rate PCA mode is difficult to match the changes in postoperative pain. This study will compare different PCA mode optimization strategies, assuming that they can reduce opioid dosage, improve analgesic effect, and reduce adverse reactions, providing high-quality evidence-based basis for postoperative analgesia and promoting individualized and intelligent management.",[28,321,322,323],"Pain Management","Opioid Consumption","Patient-controlled Analgesia","2026-06-11",{"date":326,"type":33},"2026-06-12",{"date":328,"type":33},"2025-12-30",{"date":330,"type":20},"2027-12-30",{"name":332,"class":66},"Beijing Tiantan Hospital",{"id":334,"slug":4,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":67},"100642940","NCT07648394","Research on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis","Inclusion Criteria: Age between 18 and 75 years old, male or female. Undergoing surgery for benign anorectal diseases (e.g., mixed hemorrhoids, anal fistula, anal fissure).\n\nMeeting the diagnostic criteria for postoperative constipation (e.g., fewer than 3 spontaneous bowel movements per week, or difficulty in defecation).\n\nAble to understand the study procedures and voluntarily sign the informed consent form.\n\nAble to cooperate with medication administration, follow-up visits, and data collection.\n\nExclusion Criteria:Severe organic diseases of the heart, liver, kidney, or other vital organs.\n\nHistory of inflammatory bowel disease, irritable bowel syndrome, or severe chronic constipation unrelated to surgery.\n\nHistory of gastrointestinal surgery (other than the planned anorectal surgery) within the past 3 months.\n\nPregnancy, breastfeeding, or planned pregnancy during the study period (for female participants).\n\nKnown allergy or contraindication to the study drugs (Shouhui Tongbian Capsules or lactulose).\n\nCurrent use of other laxatives, prokinetic drugs, or traditional Chinese medicine for constipation within 1 month before enrollment.\n\nSevere mental disorders, cognitive impairment, or inability to communicate effectively.\n\nParticipation in other clinical trials within the past 3 months. Any other condition judged by the investigator to make the participant unsuitable for this study.","75 Years",{"count":121,"type":20},[341,342],"PHASE1","PHASE2","Study Title A study to learn how Shouhui Tongbian Capsules works to relieve constipation after anorectal surgery, and explore its effects linked to gut bacteria.\n\nWhy we do this study Constipation is a common problem after surgery for hemorrhoids, anal fistula and other benign anorectal diseases. It causes pain, slows wound healing and lowers quality of life. Traditional laxatives may lead to stomach pain, electrolyte problems and drug dependence.\n\nShouhui Tongbian Capsules is a traditional Chinese herbal medicine. It can ease constipation and protect the intestinal tract at the same time. This research aims to check how well this medicine works for post-surgery constipation, whether it reduces pain, and find out its working mechanism related to gut microbiota. We also want to collect evidence for better combined traditional Chinese and Western medicine treatment in clinic.\n\nWho can take part Adults aged 18 to 75 who receive surgery for benign anorectal diseases and have constipation Fully aware of the study and willing to sign an informed consent form People with severe organ diseases, mental illness, cancer, bleeding disorders, pregnancy or other conditions will not be included.\n\nHow the study works\n\nThis is a prospective, randomized, controlled clinical trial. A total of 120 patients will be randomly divided into two groups (60 people each):\n\nTest group: Take Shouhui Tongbian Capsules, 2 pills three times a day for 8 weeks.\n\nControl group: Take lactulose oral solution, the common medicine for constipation.\n\nWe will assess symptoms regularly before, during and after treatment. We will record constipation severity, traditional Chinese medicine symptom scores, pain scores (VAS), quality of life (SF-36), physical signs and blood test results. We will also test gut bacteria and inflammation levels to analyze the medicine's mechanism.\n\nSafety All participants will be closely monitored throughout the study. We will record any discomfort or side effects in a timely manner to ensure safety.\n\nExpected benefits This study will confirm the effectiveness and safety of Shouhui Tongbian Capsules for post-anorectal surgery constipation. It may help relieve your constipation and post-operative pain, speed up recovery and improve daily life. The results will also help doctors choose better treatments for similar patients in the future.\n\nStudy timeline May - June 2026: Complete ethical review and study preparation July - September 2026: Recruit participants and start treatment Late 2026 - Early 2027: Finish data collection, analysis and paper writing",[345,346,28,347],"Intestinal Flora","Anorectal Diseases","Constipation","2026-06-10",{"date":108,"type":33},{"date":351,"type":20},"2026-08-01",{"date":353,"type":20},"2027-06-30",{"name":355,"class":66},"China-Japan Friendship Hospital",{"id":357,"slug":4,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":21,"phases":365,"briefSummary":366,"conditions":367,"keywords":371,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":67},"100590209","NCT06964438","Postoperative Electrical Muscle Stimulation Two","A Three-Arm Randomised Controlled Trial to Establish Effectiveness of NMES With or Without Protein Supplementation to Preserve Muscle Mass and Strength and Improve Functional Outcomes After Abdominal Surgery for GI Cancer","POEMS2","Inclusion Criteria:\n\n* Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting)\n* MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery\n* Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital\n* Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery\n* Basic conversational spoken English language\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Upper GI (gastrointestinal) cancer requiring thoracotomy\u002Fthoracoscopy\n* Pre-existing neuromuscular disease (including Parkinsons disease)\n* Pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device\n* Metal prostheses or other metal-work in either upper legs (hip\u002Fknee\u002Ffemur)\n* Dementia or other cognitive problem or language barrier causing an inability to follow instructions and operate NMES machine\n* Inability to give informed consent\n* Disability preventing completion of ERAS after surgery (requiring Zimmer frame\u002Fwheeled frame\u002Fwheelchair to mobilise or bed-bound)\n* Peripheral vascular disease\n* Epilepsy\n* Pre-existing diagnosis of chronic kidney disease or estimated glomerular filtration rate \\\u003C60 on screening visit\n* Pre-existing diagnosis of liver disease\n* Intubation or intensive care admission during study period (between day 0-5 post-op); (surgical high dependency unit patients will be included)\n* Return to theatre for surgical complication within first 5-days post operation\n* History of rhabdomyolysis\n* Pregnancy\n* Deep vein thrombosis within past 6-months\n* Allergy to whey protein\n* Patient refusal of whey protein products on grounds of dietary requirements or intolerance\n* Participating in another clinical trial concurrently or within the last 6 months\n* Known infection with blood borne virus",{"count":364,"type":20},45,[78],"Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery.\n\nThe investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery. Since then, additional work has been carried out to find the most effective form of stimulation to build muscle.\n\nThe current study aims to use this refined stimulation protocol in a clinical trial on the wards after major abdominal surgery. The intervention will involve delivering stimulation to both thighs in the few days after surgery, so that the investigators can assess whether this stimulation can preserve muscle mass and strength, and also, patients' ability to perform physical activities after surgery. In addition, the study will aim to find out whether any benefit provided by electrical stimulation can be increased further by taking a protein supplement at the same time.",[28,368,369,370],"Colorectal Cancer","Muscle Atrophy","Cancer Gi",[372,373,374,375,376,377,378,379,380,381,382],"electrical stimulation","neuromuscular electrical stimulation","NMES","rehabilitation","general surgery","colorectal surgery","laparotomy","laparoscopy","postoperative recovery","gastrointestinal cancer","gastrointestinal surgery",{"date":108,"type":33},{"date":385,"type":33},"2025-06-05",{"date":387,"type":20},"2027-03-01",{"name":389,"class":66},"University of Nottingham",{"id":391,"slug":4,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":15,"minAge":397,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":21,"phases":399,"briefSummary":400,"conditions":401,"keywords":404,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":67},"100572331","NCT06731881","Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections","Leveraging Photodynamic Therapy to Inhibit Microorganisms - Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections in Nasal Surgery Patients: A Pilot Study","LIGHT","Inclusion Criteria:\n\n* Patients ≥ 16 years\n* Patients scheduled to undergo elective:\n\n  * Endoscopic Sinus Surgery (ESS) with or without adjunctive Septoplasty and\u002For Turbinoplasty\n  * Septoplasty with or without adjunctive Turbinoplasty\n  * Closed Septoplasty with or without adjunctive Turbinoplasty\n* Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history and physical examination\n* Willing and able to provide written informed consent prior to participation in the clinical investigation\n* Willing and able to comply with all study related procedures\n\nExclusion Criteria:\n\n-• Patients undergoing open septorhinoplasty, anterior or septal biopsies, or post cautery\n\n* Congenital or acquired immunodeficiency, bone marrow disease, diabetes, autoimmune conditions requiring immunosuppressive treatment, any immunosuppressive medication at the time of consent or within the last 4 weeks before randomisation\n* Primary or secondary ciliary dyskinesia, cystic fibrosis\n* Patients who have received antibiotics within a week before randomisation\n* Patients who receive prophylactic antibiotics or antibiotics prior to discharge\n* Systemic steroid treatment less than 4 weeks before randomisation\n* History of frequent nose bleeds, or a condition that increases the risk of excessive bleeding\n* Undergoing active cancer treatment at time of consent\u002F or planning to start cancer treatment within trial period or completed cancer treatment within the last 4 weeks\n* Any disease, condition (medical or surgical), or drug or alcohol abuse, which, in the opinion of the investigator, might compromise the study results, or would place the patient at increased risk of infection\n* Previously treated with radiation on the face, head, or neck regions\n* Female patients who are pregnant or breastfeeding at the time of consent\n* Received a study drug in a clinical trial for an investigational drug within the previous 30 days from consent, or 5 half-lives, whichever is longer\n* Used antimicrobial wash or wipes within 7 days of randomisation or during the study period\n* Patients with allergies \u002F hypersensitivity to methylene blue, polymethyl methacrylate (PMMA), or to chlorhexidine gluconate (CHG)","16 Years",{"count":269,"type":20},[78],"This is a randomised, unblinded interventional device proof of concept pilot trial in which patients undergoing nasal surgery will be selected for either photodisinfection therapy (PDT) with the Steriwave™ ND System, or control with nares swabbed with 'photosensitizer formulation' preoperatively.\n\nThis trial will primarily assess the safety and efficacy of nasal photodisinfection treatment in decreasing post-operative events in patients undergoing nasal surgery. After signing informed consent, and before surgery, participants will receive a baseline culture of the anterior nares to determine nasal bacterial colonization and will have a flexible nasendoscopy to determine their Lund-Kennedy (LK) endoscopic score. Subjects will then be randomised to nasal PDT (which includes two applications of 'photosensitizer formulation' \\[0.01% methylene blue with 0.25% chlorhexidine solution\\], two minutes apart), along with light therapy, or control with nares swabbed twice with 'photosensitizer formulation' with two minutes in between (no light therapy). Following treatment, participants will be re-cultured (2 weeks after the surgery ± 7 days) and reviewed for antibiotic use and surgical site infection (SSI) using LK endoscopic scoring. At 30 days, all participants will be followed up by telephone to review if they received antibiotics for presumed postoperative infection. Standard post-operative care will be provided according to the type of surgery performed. Any required interventions post-operatively will be documented.",[28,402,403],"Nasal Disease","Light; Therapy, Complications",[405,406,407,408],"nasal surgery","nasal photodisinfection","decolonisation","surgical site infection",{"date":324,"type":33},{"date":411,"type":33},"2025-06-04",{"date":57,"type":20},{"name":414,"class":66},"Guy's and St Thomas' NHS Foundation Trust",{"id":416,"slug":4,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":240,"enrollmentInfo":421,"targetDuration":4,"studyType":21,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":67},"100539044","NCT06298721","Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs Phenotypes","Improving Total Knee Arthroplasty Dissatisfaction at 1-year Through a Personalized Approach Focusing on PROMs Phenotypes: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adult subject (Age \\>18 and \\\u003C 80 years of age)\n2. The subject is proficient in the English language\n3. The patient is voluntarily prepared to sign the 'Informed Consent Form'\n4. The patient is scheduled for a unilateral primary TKA\n5. TKA PROMs Phenotypes with higher risk of dissatisfaction\n6. Patient is willing and able to complete the protocol required follow-up\n\nExclusion Criteria:\n\n1. Patient requires simultaneous or staged bilateral knee replacements, staged \\\u003C90 days apart\n2. Patients undergoing revision TKA\n3. Inflammatory arthritis\n4. History of infection in the joint undergoing TKA\n5. Patient is considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.)",{"count":422,"type":20},300,[78],"This study is a randomized controlled trial to assess whether the implementation of a TKA Personalized Outcome Prediction Tool to set expectation, in addition to targeted interventions to address patients with poor baseline mental health and poor physical function, improves satisfaction at 1-year (when compared to standard of care).",[426,427,28],"Knee Osteoarthritis","Knee Arthropathy","2026-06-09",{"date":324,"type":33},{"date":431,"type":33},"2024-03-12",{"date":387,"type":20},{"name":434,"class":66},"The Cleveland Clinic",{"id":436,"slug":4,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":17,"enrollmentInfo":441,"targetDuration":4,"studyType":21,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":456},"100643250","NCT07641153","VR-Based Cognitive Stimulation Games for Delirium Prevention","Virtual Reality-Based Cognitive Stimulation Games for Enhancing Attention and Preventing Delirium in Older Surgical Patients With Cognitive Impairment","Inclusion Criteria:\n\n* Men and women ≥65 years of age\n* Have a pre-existing diagnosis of cognitive impairment (Montreal Cognitive Assessment Score of 15-24)\n* Elective or emergency major surgery with the expectation of admission to the Intensive Care Unit following the surgery for three days following surgery\n\nExclusion Criteria:\n\n* Pre-existing Intubation and invasive ventilation;\n* history of severe mental illness;\n* admission for a drug overdose;\n* severe vertigo;\n* history of severe postoperative nausea and vomiting;\n* hearing and visual impairment;\n* preexisting severe dementia (Montreal Cognitive Assessment Score \\\u003C 15; and\n* active delirium at the time of screening for eligibility criteria.\n* Active suicidal ideation or behavior Screen failure after surgery\n* Prolonged intubation after surgery (more than 24 hours)",{"count":442,"type":20},90,[78],"This trial aims to evaluate the feasibility, safety, and acceptability of a virtual reality (VR)-based cognitive stimulation game to reduce postoperative delirium among older surgical patients at high risk due to pre-existing cognitive impairment.",[28,446,447],"Delirium - Postoperative","Delirium","2026-06-08",{"date":324,"type":33},{"date":451,"type":33},"2026-04-24",{"date":453,"type":20},"2029-05-01",{"name":455,"class":66},"The Methodist Hospital Research Institute",2,{"id":458,"slug":4,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":119,"minAge":463,"maxAge":240,"enrollmentInfo":464,"targetDuration":4,"studyType":21,"phases":465,"briefSummary":466,"conditions":467,"keywords":471,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":482,"leadSponsor":484,"locationsCount":67},"100643185","NCT07626151","Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy","Effect Of Standard Versus Restricted Fluid Therapy Guided By Electric Cardiometry On Tissue Perfuison In Robotic Prostaectomy: A Randomized Controlled Study","Inclusion Criteria:\n\n* Male patient undergoing robotic assisted prostatectomy\n* ASA I-III\n\nExclusion Criteria:\n\n* ASA score more than III\n* BMI more than 40\n* Severe renal disease (GFR between 15 and 29)\n* Previous renal surgery.\n* Decompensated cardiac disease (NYHA class 3 or 4)","40 Years",{"count":442,"type":20},[78],"Fluid therapy during surgery is an important factor that is related to long term mortality and morbidity and it's directly related to tissue perfusion as well. The main target in any surgery is what is the optimum fluid therapy to maintain the tissue perfusion and the precise balance between hazardous effects of hypervolemia that may cause delayed wound healing due to surgical anastomosis disruption or being hypovolemic that may cause tissue ischemia as acute kidney injury.\n\nFluid management guidance changed from static methods like central venous pressure into dynamic methods like pulse pressure variation (PPV) and stroke volume variation (SVV), which are now the most famous dynamic measures.\n\nElectrical cardiometry is a non-invasive cardiac output monitor which uses electrical cardiometry, now a commonly used device, to measure SVV which can be used to guide fluid therapy during surgeries.\n\nNow robotic assisted surgery is a common method in preforming many surgeries especially urological, since it's associated with numerous desirable outcomes including shorter post-operative stay and faster return to preoperative function.\n\nWith considerations related to severe Trendelenburg position and increased intra-abdominal pressure due to pneumo-peritoneum, robotic assisted surgeries are associated with many challenges in anesthesia especially the fluid therapy.\n\nFluid therapy in robotic surgeries is an area with growing research focus that need further exploration while there are established guidelines for fluid management in traditional surgeries, the optimal protocols for robotic surgeries are less well defined, needing more research.\n\nWe aim at this study to investigate the impact of liberal versus restricted fluid intake on the tissue perfusion reflected by serum lactate \\& creatinine clearance, while guiding therapy through electrical cardiometry, to reach optimum fluid protocol in prostatic robotic surgeries.",[468,28,469,470],"Prostate Cancer","Fluid Overload","Lactate Blood Increase",[472,473,474,475,476,477,478],"Robotic","Prostatectomy","Sugery","Anesthesia","Fluid","Electric Cardiometry","Tissue Perfusion","2026-06-05",{"date":448,"type":33},{"date":479,"type":33},{"date":483,"type":20},"2026-12",{"name":485,"class":66},"Nazmy Edward Seif",{"id":487,"slug":4,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":338,"enrollmentInfo":492,"targetDuration":4,"studyType":21,"phases":494,"briefSummary":495,"conditions":496,"keywords":500,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":4},"100639385","NCT07608159","Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","A Randomized, Controlled, Multicenter Phase III Clinical Study of Spatially Fractionated Stereotactic Body Radiotherapy Plus Toripalimab and Chemotherapy Versus Toripalimab Plus Chemotherapy in Patients With Resectable or Potentially Resectable Stage II-III Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Male or female participants aged 18 to 75 years;\n* Eastern Cooperative Oncology Group performance status of 0 or 1;\n* Previously untreated, pathologically confirmed, resectable or potentially -resectable stage II, IIIA, or IIIB (N2) non-small cell lung cancer according to the 8th edition of the American Joint Committee on Cancer staging system;\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1;\n* Adequate pulmonary function, as assessed by the surgeon, to tolerate the planned lung resection;\n* Absence of sensitizing EGFR mutations or ALK rearrangements confirmed by tissue-based molecular pathological testing;\n* Adequate organ function, defined as follows:\n\nBone marrow function: absolute neutrophil count ≥1.5 × 10\\^9\u002FL, platelet count ≥80 × 10\\^9\u002FL, and hemoglobin ≥9 g\u002FdL; Liver function: total serum bilirubin ≤1.5 × upper limit of normal; alanine aminotransferase and aspartate aminotransferase ≤1.5 × upper limit of normal; Renal function: serum creatinine ≤1.5 × upper limit of normal or creatinine clearance ≥60 mL\u002Fmin, and blood urea nitrogen ≤200 mg\u002FL;\n\n* Participants must be fully informed about the study and voluntarily sign the written informed consent form.\n* Male participants with reproductive potential or female participants of childbearing potential must agree to use effective contraception during the study, such as oral contraceptives, an intrauterine device, or a barrier method combined with spermicide, and continue contraception for 6 months after completion of treatment.\n\nExclusion Criteria:\n\n* Locally advanced unresectable or metastatic disease. Unresectable disease is defined according to the multidisciplinary consensus for stage III non-small cell lung cancer (2019 edition), including some stage IIIA, stage IIIB, and all stage IIIC disease. This usually includes N2 disease with a single-station mediastinal lymph node with a short-axis diameter ≥3 cm, or multistation lymph node fusion\u002Fconglomeration with lymph nodes having a short-axis diameter ≥2 cm on CT; T4 disease invading the esophagus, heart, aorta, or pulmonary veins; and all N3 disease;\n* Non-small cell lung cancer involving the superior sulcus, large-cell neuroendocrine carcinoma, or sarcomatoid carcinoma;\n* Known sensitizing EGFR mutation or ALK rearrangement. For participants with non-squamous histology, EGFR and ALK mutation status must be confirmed;\n* Prior treatment with PD-1 or PD-L1 inhibitors, or agents targeting another T-cell receptor pathway, such as CTLA-4 or OX-40;\n* Active or suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. Exceptions include type 1 diabetes mellitus or hypothyroidism controlled with stable replacement therapy, and dermatologic conditions not requiring systemic treatment, such as psoriasis or vitiligo;\n* History of interstitial lung disease of grade 2 or higher;\n* Use of systemic corticosteroids, defined as prednisone \\>10 mg\u002Fday or equivalent, or other immunosuppressive medications within 14 days before the first dose of study treatment;\n* History of immunodeficiency, including acquired or congenital immunodeficiency disorders, history of organ transplantation, or prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n* Receipt of a live vaccine within 4 weeks before the first dose of study treatment;\n* Severe cardiovascular or cerebrovascular disease, including:\n\nPoorly controlled hypertension or pulmonary hypertension;\n\n* Unstable angina, myocardial infarction, coronary artery bypass grafting, or coronary stent implantation within 6 months before study treatment;\n* Chronic heart failure with New York Heart Association class II or higher cardiac function;\n* Left ventricular ejection fraction \\\u003C50%;\n* Severe arrhythmias requiring medical treatment, except atrial fibrillation or paroxysmal supraventricular tachycardia. Examples include QTcF \\>450 msec in males or \\>470 msec in females, complete left bundle branch block, or third-degree atrioventricular block;\n* Cerebrovascular accident or transient ischemic attack within 6 months before study treatment;\n* Uncontrolled or severe underlying medical conditions, including but not limited to active infection requiring systemic antibiotic therapy;\n* Positive human immunodeficiency virus antibody test, active hepatitis B, or active hepatitis C. The following participants may be eligible:\n* Participants positive for hepatitis B core antibody or hepatitis B surface antigen may be enrolled if HBV DNA is below the lower limit of detection at the study site, or \\\u003C500 IU\u002FmL, and active infection is excluded by the investigator based on clinical treatment history and clinical manifestations;\n* Participants positive for hepatitis C antibody may be enrolled if HCV RNA is below the lower limit of detection at the study site;\n* Known active pulmonary tuberculosis. Participants suspected of having active tuberculosis must undergo chest X-ray, sputum examination, and assessment of clinical symptoms and signs to exclude active tuberculosis;\n* History of any active malignancy other than the study disease within 2 years before enrollment, except malignancies expected to be cured after treatment, including but not limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with curative surgery;\n* History of psychotropic drug abuse that cannot be discontinued, or history of psychiatric disorder;\n* Pregnant or breastfeeding women;\n* Any other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that, in the investigator's judgment, may increase the risk associated with study participation or may interfere with interpretation of the study results.",{"count":493,"type":20},201,[52],"This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and platinum-based chemotherapy versus toripalimab combined with platinum-based chemotherapy in patients with resectable or potentially resectable stage II-III non-small cell lung cancer (NSCLC). Eligible participants will be randomized 2:1 to receive either neoadjuvant SF-SBRT followed by toripalimab and platinum-based chemotherapy for two cycles, or toripalimab and platinum-based chemotherapy for three cycles. Randomization will be stratified by disease stage and histological subtype. Surgery is planned 4-6 weeks after completion of neoadjuvant treatment, and postoperative adjuvant therapy will be determined by the investigator. The primary endpoint is the 2-year event-free survival rate. Secondary endpoints include pathological complete response rate, major pathological response rate, objective response rate, R0 resection rate, event-free survival, overall survival, and safety. Adverse events will be assessed according to NCI CTCAE version 5.0 or later.",[497,498,499,28],"Non Small Cell Lung Cancer","Stereotactic Body Radiotherapy","Neoadjuvant Chemoimmunotherapy",[501,502,503,504],"Spatially fractionated radiotherapy","stereotactic body radiotherapy","non small cell lung cancer","neoadjuvant chemoimmunotherapy","2026-05-27",{"date":507,"type":33},"2026-05-29",{"date":509,"type":20},"2026-05",{"date":511,"type":20},"2030-05",{"name":513,"class":66},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":515,"slug":4,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":67},"100538856","NCT06296277","Mechanical Ventilation in Surgical Patients","Management of Mechanical Ventilation During Surgery: an International, Multicenter, and Observational Data Registry","MEET VENUS","Inclusion Criteria:\n\n* Adults; and\n* Receiving intraoperative IMV (via tracheal intubation, or supraglottic device ) during general anesthesia for surgery\n\nExclusion Criteria:\n\n* Receiving intraoperative IMV outside of an operating room; and\n* Receiving intraoperative IMV during extracorporeal life support",{"count":522,"type":20},10000,"This is an investigator-initiated, international, multicenter, prospective, cross-sectional study that aims to 1) describe the incidence and types of postoperative pulmonary complications (PPCs), 2) describe patient demographics, baseline characteristics, and intraoperative ventilation management, 3) describe the occurrence of intraoperative adverse events (IAEs), and 4) their associations with PPCs, 5) assess the practice of intraoperative mechanical ventilation.\n\nPatients will be eligible for participation if: 1) adult and 2) receiving intraoperative ventilation during general anesthesia for surgery. Patients receiving ventilation outside of an operating room as well as patients receiving intraoperative ventilation during extracorporeal life support will be excluded",[28,525,526],"Ventilator Lung","Postoperative Complications","2026-05-25",{"date":529,"type":33},"2026-05-28",{"date":531,"type":33},"2026-03-01",{"date":533,"type":20},"2027-08-31",{"name":535,"class":66},"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria",{"id":537,"slug":4,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":21,"phases":545,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":67},"100533980","NCT06232876","Continuous Versus Intermittent Ward Monitoring","Continuous Versus Intermittent Ward Monitoring on Vital Sign Abnormalities, Clinical Interventions, and Serious Complications: the CONSTANT Trial","CONSTANT","Inclusion Criteria:\n\n1. Are admitted to one of the wards equipped with the Masimo Radius PPG and Rad-97 monitors;\n2. Are ≥18 years old;\n3. Are designated American Society of Anesthesiologists physical status 1-4;\n4. Had major noncardiac surgery lasting at least 1.5 hours;\n5. Are expected to remain hospitalized at least two postoperative nights;\n6. Had general anesthesia with or without neuraxial anesthesia.\n\nExclusion Criteria:\n\n1. Have language, vision, or hearing impairments that may compromise continuous monitoring;\n2. Are designated Do Not Resuscitate, hospice, or receiving end of life care;\n3. Have previously participated in the study.",{"count":544,"type":20},492,[78],"The investigators will randomize adults having major non-cardiac inpatient surgery to blinded versus unblinded continuous postoperative vital sign monitoring (saturation, ventilation, and heart rate). The investigators will use a wearable, untethered, and battery-powered sensor (Masimo Radius PPG, Masimo, Irvine, CA) that wirelessly connects to a Masimo monitor and continuously records saturation, ventilation, and pulse rate.\n\nThe primary outcome will be areas-exceeding-thresholds for desaturation (\\\u003C85%), bradypnea (\\\u003C7 breaths\u002Fmin), tachypnea (\\>30 breaths\u002Fmin), tachycardia (heart rate \\>130 beats\u002Fmin), and bradycardia (heart rate \\\u003C45 beats\u002Fmin). These exposure thresholds represent a balance between events that are clinically meaningful and excessive alarms that will discourage clinician participation. The investigators expect about 1 alert per patient per day with these thresholds, with most being considered informative or actionable by nurses. In unblinded patients, clinician alerts will be activated at these thresholds.",[28],[549,550,28,551],"monitoring","Vital signs","Postoperative","2026-05-24",{"date":529,"type":33},{"date":555,"type":20},"2026-06-01",{"date":557,"type":20},"2029-03-01",{"name":559,"class":66},"The University of Texas Health Science Center, Houston",{"id":561,"slug":4,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":21,"phases":567,"briefSummary":568,"conditions":569,"keywords":573,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":67},"100634527","NCT07540845","Regular Diet After Colorectal Surgery","Impact of Postoperative Regular Diet on Colorectal Outcomes and Patient Quality of Life","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Scheduled to undergo colorectal resection\n\nExclusion Criteria:\n\n* Patients with bowel obstructions\n* Patients below the age of 18",{"count":184,"type":20},[78],"The goal of this pilot study is to assess the safety and feasibility of regular diet after surgical removal of the colon. The study will enroll patients preoperatively, prior to colon surgery, and will follow participants for up to 30 days. The study hypothesizes that simplifying nutritional recommendations is safe and may improve quality of life.",[570,571,28,572],"Colorectal","Diet Habits","Post-operative Care",[574,575],"diet after surgery","nutrition counseling","2026-05-20",{"date":578,"type":33},"2026-05-22",{"date":580,"type":33},"2026-05-13",{"date":582,"type":20},"2027-01-31",{"name":584,"class":66},"Weill Medical College of Cornell University",{"id":586,"slug":4,"hasResults":11,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":21,"phases":593,"briefSummary":594,"conditions":595,"keywords":599,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":603,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":610},"100542051","NCT06337838","Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial","BRACKETS","Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:\n\n1. One of either:\n\n   1.1. eGFR \\\u003C25 ml\u002Fmin\u002F1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;\n2. Planned noncardiac surgery (elective, urgent, or emergency surgery);\n3. Expected to require at least an overnight hospital admission after surgery;\n4. Age ≥18 years; and\n5. Informed consent is obtained to participate in the BRACKETS-Pilot Trial.\n\nExclusion Criteria:\n\n1. Undergoing cardiac surgery;\n2. Undergoing intracranial neurosurgery;\n3. Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access;\n4. Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid;\n5. Hypersensitivity or known allergy to TXA;\n6. History of seizure disorder;\n7. Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft;\n8. History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome;\n9. Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of childbearing potential and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective contraception; or\n10. Previously enrolled in the BRACKETS-Pilot Trial.\n\nEligibility criteria specific to the desmopressin factorial component of trial\n\nInclusion criteria:\n\n1\\. Included in the TXA factorial.\n\nExclusion criteria:\n\n1. The hospital does not have access to desmopressin;\n2. Planned use of prophylactic desmopressin;\n3. Most recent serum sodium concentration \\\u003C 130 mEq\u002FL;\n4. Known or suspected von Willebrand disease (any kind), hemophilia, or platelet function disorder; or\n5. Hypersensitivity or known allergy to desmopressin.",{"count":19,"type":20},[52],"The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.",[596,597,598,28],"Chronic Kidney Diseases","Acute Kidney Injury","Bleeding",[600,601,602],"Major Noncardiac Surgery","Tranexamic Acid","Desmopressin",{"date":578,"type":33},{"date":605,"type":33},"2025-06-09",{"date":607,"type":20},"2027-06",{"name":609,"class":66},"Hamilton Health Sciences Corporation",3,{"id":612,"slug":4,"hasResults":11,"nctId":613,"briefTitle":614,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":619,"conditions":620,"keywords":622,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":67},"100637996","NCT07603622","Perioperative Predictive Value of Physical Activity on Short- and Long-term Morbidity and Mortality","PeriopPrePA","Inclusion Criteria:\n\n* Adult patients (equal to or over 18 years) undergoing elective non-cardiac surgery at the two study sites, Karolinska University Hospital Solna and Karolinska University Hospital Huddinge\n\nExclusion Criteria:\n\n* Patients under the age of 18, transplant, day surgery, acute surgery, anesthesia monitoring, brachy therapy and gamma knife interventions. In case of multiple surgeries, only the first will be included.",{"count":618,"type":20},50000,"Over 300 million surgeries are performed globally every year. Complications after surgery - infections, cardiovascular conditions, postoperative pulmonary complications and renal impairment - affect survival and quality of life.\n\nAge and co-morbidity are unmodifiable factors, contributing to increased risk of these perioperative complications. However, a modifiable risk factor is physical activity. This study aims to test if self reported physical activity has added predicted value, beyond established risk factors, for predicting perioperative morbidity and mortality.",[475,28,621],"Surgery Complications",[623,624,625,626],"Perioperative medicine","Outcome","Mortality","Morbidity","2026-05-18",{"date":578,"type":33},{"date":630,"type":20},"2026-05-01",{"date":632,"type":20},"2026-11-30",{"name":634,"class":66},"Karolinska Institutet",""]